DEVELOPMENT PHARMACEUTICS AND PROCESS VALIDATION
|
|
- Blaze Freeman
- 5 years ago
- Views:
Transcription
1 DEVELOPMENT PHARMACEUTICS AND PROCESS VALIDATION Guideline Title Development Pharmaceutics and Process Validation Legislative basis Directive 75/318/EEC as amended Date of first adoption April 1988 Date of entry into October 1988 force Status Last revised 1988 Previous titles/other None references Additional Notes This note for guidance concerns the application of Part 2, sections A.4 and B of the Annex to Directive 75/318/EEC as amended with a view to the granting of a marketing authorisation for a medicinal product. CONTENTS I DEVELOPMENT PHARMACEUTICS 1. INTRODUCTION 2. CONSTITUENTS 3. COMPOSITION 4. CONTAINER II PROCESS VALIDATION 3
2
3 DEVELOPMENT PHARMACEUTICS AND PROCESS VALIDATION I. DEVELOPMENT PHARMACEUTICS 1. INTRODUCTION Pharmaceutical development studies may need to be carried out to establish that the type of dosage form selected and the formulation proposed are satisfactory for the purpose specified in the application. They also aim to identify those formulation and processing aspects that are crucial for batch reproducibility and which therefore need to be monitored routinely. Because of the great variety in active substances and dosage forms, this note for guidance is only an illustration of the type of information which has been found useful in establishing the factors which affect quality of a finished product. 2. CONSTITUENTS 2.1 Active substances Compatibility The compatibility of the active substance(s) with the excipients should, where necessary, be demonstrated Physical characteristics It may be necessary to study the effect of such parameters as e.g. crystal form, moisture content and particle size of the active substance on the formulation. The latter may be of importance in bioavailability, content uniformity, suspension properties, stability and for eye irritation studies. Having identified a parameter as being critical, its control should then be reflected in the active substance specification, or dealt with by other appropriate means Overage Overages are primarily employed to cover losses during manufacture, i.e. manufacturing overage, and/or during shelf life, stability overage. The inclusion of any overage should be justified. 2.2 Excipients An explanation should be provided with regard to the function of the excipients in the formulation Excipient compatibility should be established where relevant. 5
4 3AQ1a Where unusual excipients are used in the manufacture of the product, e.g. the matrix of a slow release preparation, full information on the composition and function of the excipient in the formulation of the product should be furnished together with any documentation which may be available to demonstrate safety of the raw material. A new substance introduced as an excipient will be regarded in the same way as a new active substance, unless it is already approved for use in food by the same route of administration. 3. COMPOSITION 3.1 Liquid dosage forms Physical parameters a) p H Evidence should be presented to show that the effect of ph within the specified range of the formulation has been investigated. Consideration should be given to the effect of ph on active constituent(s), and, where relevant, on the antimicrobial efficacy. Should such a study show positive results any long-term effects would need to be investigated during stability studies. b ) others Depending on the formulation, such parameters as ease of dissolution and redispersion, particle size, aggregation, rheological properties, etc. should also be considered during pharmaceutical development studies. In the formulation of parenteral products, consideration may have to be given to such factors as tonicity adjustment, globule size of emulsions, particle size and shape as well as changes in crystal form, etc Additives preservatives, antioxidants, others. The concentration of additive(s) incorporated into the formulation should be shown by experimental results to be optimum for the intended usage. Consideration should therefore be given to such factors as storage, reconstitution and dilution before use and frequency of opening the pack when choosing suitable level(s) of additive(s) and designing tests to establish efficacy of a preservative system. Large packs intended for dispensing purpose may require more stringent testing. Both antibacterial and antifungal efficacy should be demonstrated and the test should include suitable positive and negative controls. Testing conditions and the results thereby obtained must be reported Compatibility with other products This is of particular importance for products to be administered intravenously. Where the data sheet gives instructions for dilution before administration, data should be presented to demonstrate physical and chemical compatibility with the recommended diluents over the recommended or anticipated period of use. 6
5 3.2 Semi-solid dosage forms Physical parameters a) p H Evidence should be presented to show that the effect of ph within the specified range of the formulation, where relevant, including preservative activity, has been investigated. Where a significant effect is observed, any long-term effects would need to be investigated during stability studies. b ) others Where the active substance is suspended rather than dissolved, particle size control and particle size aggregation should be taken into consideration during development studies. Rheology studies may also need to be carried out during the development of semi-solids Additives preservatives, antioxidants, others. The concentration of additive(s) incorporated into the formulation should be shown by experimental results to be optimum for the intended usage. Consideration should therefore be given to such factors as storage, reconstitution, dilution before use and frequency of opening the pack when choosing suitable level(s) of additive(s) and designing tests to establish the efficacy of the preservative system. In such tests, both antibacterial and anti fungal efficacy should be demonstrated and the test should include suitable positive and negative controls. Testing conditions and the results thereby obtained must be reported. 3.3 Solid dosage forms Dissolution The dissolution apparatus used in the testing of both unmodified and modified release preparations should be either of those described in the European Pharmacopoeia. Where these prove unsuitable, dissolution test equipment described in the National Pharmacopoeia of the Member State should be adopted as second choice, or, failing this, any other method. However, justification for the use of a method other than European Pharmacopoeia must be put forward. a) Unmodified release preparations Dissolution tests must be performed during development and stability studies in order to establish whether such testing would need to be done during stability studies and routinely as part of the finished product specification. b ) Modified release preparations The choice of dissolution test conditions and release rates adopted for assessing batch reproducibility needs to be justified. This should take account of in vivo studies carried out to establish the release and absorption profile of the product and would, if feasible, consist of a study correlating in vitro release rates to in vivo results to allow meaningful batch 7
6 3AQ1a reproducibility evaluation. Such a correlation would be of particular importance for medicinal products containing active substances with a narrow therapeutic window. A significant change in composition, method or site of manufacture or equipment, control tests on starting materials or finished product may however necessitate further in vitro correlation studies or in vivo bioavailability studies Homogeneity The European Pharmacopoeia includes a requirement for uniformity of content of singledose preparations where the amount of active constituent is less than 2 mg per dose or less than 2% by mass of the total mass. Notwithstanding this requirement, the adequacy of the mixing process in obtaining the required homogeneity of the mixture ought to be considered for all solid dose forms i.e., tablets, powders, etc. 4. CONTAINER Appropriate studies should be performed to demonstrate the integrity of the container and closure. A possible interaction between product and container may need to be considered. 4.1 Sorption to container Data should be presented to show that consideration has been given to the possibility of sorption of the active constituent(s) and additive(s) from liquid or semi-solid formulations i f relevant to safety or stability. These phenomena are known to occur with rubber closures and with both glass and plastic containers and administration sets. Where evidence exists for significant sorption to administration sets, the data sheet should include an appropriate reference to this fact. 4.2 Leaching Data should be presented to show that there is no significant leaching of any pack component, including label adhesive, into liquid or finely divided solid preparations over the shelf life period, where relevant. 4.3 Dose reproducibility If a dosing device is used, evidence should be presented that a reproducible dose of the product is delivered under testing conditions, which, as far as possible, are relevant for the use of the product by the patient. 8
7 II. PROCESS VALIDATION Whereas development pharmaceutics is concerned with establishing that the proposed formulation is satisfactory for the purpose specified, process validation is intended to establish that the proposed manufacturing process is a suitable one and yields consistently a product of the desired quality. While process validation is generally a concept more closely associated with Good Manufacturing Practice (GMP) and therefore falling into the area of inspections, if a non-standard method of manufacture is used or if certain aspects of the method of manufacture are crucial for product quality, efficacy or safety but cannot necessarily be detected by analytical means, data on process validation may be required i n applications for marketing authorisation for a medicinal product. Areas mostly concerned are process environment, process equipment and the manufacturing process itself, the latter being the most important one. Thus data may be required to establish e.g. that: non-standard sterilisation conditions provide an acceptable level of assurance of product sterility, or the manufacturing process for a modified release system will only vary to an extent that will still yield a product of the desired quality and not have any effect on product efficacy or safety. 9
COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE:
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit - FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: DEVELOPMENT PHARMACEUTICS FOR VETERINARY
More informationQUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS
QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS Guideline Title Quality of Prolonged Release Oral Solid Dosage Forms Legislative basis Directive 75/318/EEC as amended Date of first adoption October
More informationQ8 Pharmaceutical Development
Q8 Pharmaceutical Development For questions regarding this draft document contact (CDER) Ajaz Hussain at 301-594-2847 or (CBER) Christopher Joneckis at 301-435-5681. This draft guidance, when finalized,
More informationGuidelines for Pharmaceutical Equivalence Requirements
Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 1 September 2010 Page 1 of 9 Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 Drug Sector Saudi Food & Drug Authority
More informationICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
More informationCLINICAL REQUIREMENTS FOR LOCALLY APPLIED, LOCALLY ACTING PRODUCTS, CONTAINING KNOWN CONSTITUENTS
CLINICAL REQUIREMENTS FOR LOCALLY APPLIED, LOCALLY ACTING PRODUCTS, CONTAINING KNOWN CONSTITUENTS Guideline Title Clinical Requirements for Locally Applied, Locally Acting Products, Containing Known Constituents
More informationMINISTRY OF HEALTH AND SOCIAL SERVICES
MINISTRY OF HEALTH AND SOCIAL SERVICES NAMIBIA MEDICINES REGULATORY COUNCIL POST REGISTRATION AMENDMENT GUIDELINES These guidelines are meant to provide assistance to industry and health care professionals
More informationPHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS
RADIOPHARMACEUTICALS Guideline Title Radiopharmaceuticals Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC Date of first adoption December 1990 Date of entry into June
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: MANUFACTURE OF THE FINISHED DOSAGE FORM
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/CVMP/126/95 FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: MANUFACTURE OF THE
More informationGUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE IA AND TYPE IB NOTIFICATIONS July 2003
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Single market : management & legislation for consumer goods Pharmaceuticals : regulatory framework and market authorisations Final Revision 0 NOTICE TO
More informationGUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product
GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product Published by authority of the Minister of Health Date Adopted 2017/11/24 Effective Date 2017/11/24 Health Products
More informationPublic Assessment Report. Scientific discussion. Natriumfusidat LEO 30 mg/100 cm 2 impregnated dressing. (Sodium fusidate) DK/H/2431/001/DC
Public Assessment Report Scientific discussion Natriumfusidat LEO 30 mg/100 cm 2 impregnated dressing (Sodium fusidate) DK/H/2431/001/DC 23 November 2015 This module reflects the scientific discussion
More informationVALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)
VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *) Guideline Title Validation of Analytical Procedures: Methodology Legislative basis Directive 75/318/EEC as amended Date of first adoption December 1996
More informationREPUBLIC OF MAURITIUS APPLICATION FOR REGISTRATION OF A DRUG
SCHEDULE Form 1 REPUBLIC OF MAURITIUS APPLICATION FOR REGISTRATION OF A DRUG THE REGISTRAR PHARAMCY BOARD MINISTRY OF HEALTH AND QUALITY OF LIFE MAURITIUS Fax: Telephone: TYPE OF APPLICATION HUMAN, BIOLOGICAL
More informationSTABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE STABILITY TESTING OF NEW DRUG SUBSTANCES AND PRODUCTS
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE
More informationFOOD AND DRUGS AUTHORITY
G H A N A FOOD AND DRUGS AUTHORITY GUIDELINES FOR STABILITY TESTING OF ACTIVE PHARMACEUTICAL INGREDIENTS AND FINISHED PHARMACEUTICAL PRODUCTS Document No: FDA/DRI/DER/GL-STP/2013/07 Date of First Adoption:
More informationReflection paper on the dissolution specification for generic solid oral immediate release products with systemic action
10 August 2017 EMA/CHMP/CVMP/QWP/336031/2017 Committee for Medicinal Products for Human use (CHMP) Committee for Medicinal Products for Veterinary use (CVMP) Quality Working Party (QWP) Reflection paper
More informationPharmaceutical development of multisource (generic) finished pharmaceutical products points to consider
Annex 3 Pharmaceutical development of multisource (generic) finished pharmaceutical products points to consider 1. Introduction 92 1.1 General principles 92 1.2 Scope 92 2. Predevelopment activities 93
More informationA STANDARD PROTOCOL for DERIVING and ASSESSMENT of STABILITY. Part 3 Oral Liquid Medicines (Solutions, Emulsions, Suspensions and Syrups)
A STANDARD PROTOCOL for DERIVING and ASSESSMENT of STABILITY Part 3 Oral Liquid Medicines (Solutions, Emulsions, Suspensions and Syrups) EDITION 1 August 2014 NHS Pharmaceutical Quality Assurance Committee
More informationGUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET
GUIDELINES FOR INTRODUCING A LOCALLY MANUFACTURED NEW PHARMACEUTICAL PRODUCT ON THE UGANDA MARKET National Drug Authority Head Office Rumee Towers Plot 19, Lumumba Avenue P. O. Box 23096 Kampala, Uganda
More informationMedicine Variations Guideline
Medicine Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 30 th March 2017 Version 2.0 Chief of Pharmaceutical Product Regulation: Dr/Roaya Al Abbasi Date: NHRA CEO Approval:
More informationINTER CHANGEABILITY and EQUIVALENCE. Where we are and what we still have to determine!
INTER CHANGEABILITY and EQUIVALENCE Where we are and what we still have to determine! Acknowledgement Joint presentation UNICEF/MSF/ICRC Cecile Mace Jean Michel Caudron Birgit Schmauser What do we mean
More informationOn the Q&A to the Guideline for Common Technical Documents
To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare
More informationWHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles
More informationMANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS
ANNEX 13 MANUFACTURE OF INVESTIGATIONAL MEDICINAL PRODUCTS Introduction Medicinal products intended for research and development trials are not at present subject either to marketing or manufacturing Community
More informationMedicines Variations Guideline
Medicines Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 27/08/2014 Version 1.1 Chief of Pharmaceutical Product Regulation: Dr / Roaya Al Abbasi Date: NHRA CEO Approval:
More informationDECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE
DECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE Determine impurity level in relevant batches 1 Determine mean + upper confidence limit for the impurity
More informationA GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Pharmaceuticals and cosmetics Final Revision 0 NOTICE TO APPLICANTS A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999 This guideline
More informationMedicines Control Authority of Zimbabwe
EFV... QUALITY INFORMATION SUMMARY (QIS) FOREWORD The Quality Information Summary (QIS) template should be completed to provide a condensed summary of the key quality information for product dossiers (PDs)
More informationName. Canazole Clotrimazole Cream 1% w/w
Annex I List of the names, pharmaceutical form, strength of the medicinal product, route of administration, applicant / marketing authorisation holder in the Member States Member State EU/EEA Marketing
More informationQbD in developing semisolid formulations
QbD in developing semisolid formulations 4th Jerusalem Conference on Quality and Pharma Sciences Haim Barsimantov, COO, Sol-Gel 21.05.13 Outline Drug Product Specification - definition In Process Control
More informationGLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE
GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Finished Pharmaceutical Product Questionnaire This questionnaire is used to collect information from vendors with regards to finished pharmaceutical products
More informationEUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL. EudraLex The Rules Governing Medicinal Products in the European Union
EUROPEAN COMMISSION ENTERPRISE AND INDUSTRY DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, 25 October 2005 EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 EU
More informationAPPLICATION FOR MARKETING AUTHORIZATION OF A PHARMACEUTICAL PRODUCT FOR HUMAN USE IN UGANDA
National Drug Authority Plot No. 46-48 Lumumba Avenue, P.O. Box 23096, Kampala, Uganda. email: ndaug@nda.or.ug; website: www.nda.or.ug Doc. No.: DAR/FOM/170 Revision No.: 1 Effective Date: 21 June 2016
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationTEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW VETERINARY DRUG SUBSTANCES AND NEW MEDICINAL PRODUCTS: CHEMICAL SUBSTANCES
VICH GL39 (QUALITY) November 2005 For implementation at Step 7 TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW VETERINARY DRUG SUBSTANCES AND NEW MEDICINAL PRODUCTS: CHEMICAL SUBSTANCES Recommended for
More informationPHOTOSTABILITY TESTING OF NEW ACTIVE SUBSTANCES AND MEDICINAL PRODUCTS *)
PHOTOSTABILITY TESTING OF NEW ACTIVE SUBSTANCES AND MEDICINAL PRODUCTS *) Guideline Title Photostability Testing of New Active Substances and Medicinal Products *) Legislative basis Directive 75/318/EEC
More informationInspection. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Outline Aim of - as a key part of the regulatory
More informationControl Strategy. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 Control Strategy International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of this session
More information2-2 Sterile Product Assessment. Satish Mallya Ph.D Training Workshop CPH, May 2015
2-2 Sterile Product Assessment Satish Mallya Ph.D Training Workshop CPH, May 2015 Focus Overview of Regulatory Requirements Tips for Critical Thinking Issues and Solutions Regulatory Requirements - Overview
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) GUIDELINE FOR AN ASSESSOR PREPARING ASSESSMENT REPORTS FOR VETERINARY MEDICINAL PRODUCTS
European Medicines Agency Veterinary Medicines and Inspections London, 18 May 2005 Doc. Ref. EMEA/CVMP/115769/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) GUIDELINE FOR AN ASSESSOR PREPARING
More informationREGULATION (EC) No 542/95
REGULATION (EC) No 542/95 Commission Regulation (EC) No 542/95 of 10 March 1995 concerning the examination of variations to the terms of a marketing authorization falling within the scope of Council Regulation
More informationApplication of Quality by Design (QbD) in product development. James E. Polli September 16, 2015
Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route
More informationADVANTAGES OF MULTIPARTICULATES (PELLETS):
INTRODUCTION: Multiparticulate Drug Delivery Systems (MDDS): The concept of multiple unit dosage form was initially introduced in the early 1950 s.these forms play a major role in the design of solid dosage
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. EudraLex. The Rules Governing Medicinal Products in the European Union
Ref. Ares(2014)968036-28/03/2014 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products quality, safety and efficacy Brussels, 28 March 2014 EudraLex
More informationSCIENTIFIC DISCUSSION
SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:
More informationThe GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G
The GCC Guidelines for Stability Testing of Drug Substances and Pharmaceutical Products EDITION TWO 1428 H 2007 G (1) INTRODUCTION The following guideline defines the stability data package for a drug
More informationDraft regional guidelines on stability testing of active substances and pharmaceutical products
Regional Committee for the EM/RC53/12 Eastern Mediterranean August 2006 Fifty-third Session Original: Arabic Agenda item 17 Draft regional guidelines on stability testing of active substances and pharmaceutical
More informationHow to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 17 December 2003 CPMP/QWP/122/02, rev 1 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) GUIDELINE
More informationAPPLICATION FOR VARIATION TO A MARKETING AUTHORISATION
Page 1 of 13 May 2008 APPLICATION FOR VARIATION TO A MARKETING AUTHORISATION HUMAN VETERINARY NATIONAL AUTHORISATION IN MRP MRP variation number 1A : / / / / / COMMUNITY AUTHORISATION EMEA variation number
More informationGUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA
GUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA Issued by the Registrar: Act No. 36 of 1947, Private Bag X343, Pretoria 0001 Republic of South Africa Tel. (**27
More informationPublic Assessment Report. Scientific discussion
Public Assessment Report Scientific discussion Moxalole Powder for oral solution (Macrogol 3350, sodium chloride, sodium hydrogen carbonate, potassium chloride) DK/H/1199/001/DC This module reflects the
More informationCHECKLIST FOR VARIATIONS APPLICATIONS FOR MEDICINES
CHECKLIST FOR VARIATIONS APPLICATIONS FOR MEDICINES INTRODUCTION: This document describes the requirements of a Variation application submitted for an existing application for registration of medicine
More informationUSP s Perspective on Drug Product Performance Test
USP s Perspective on Drug Product Performance Test Course Overview 1. The concept of in vitro dissolution Definition and application 2. Compendial dissolution/ drug release testing 3. Method development
More informationConsultation by a notified body on an ancillary medicinal substance integrated in a medical device
Consultation by a notified body on an ancillary medicinal substance integrated in a medical device Documentation requirements for an initial consultation Language : French or English Because of the wide
More informationSCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationBalancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL
Balancing the time, cost and risk of drug development Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Communicating vessels Risk Time Cost Communicating vessels
More informationRegulatory Assessment
Implementation of ICH Q8, Q9, Q10 Regulatory Assessment International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Presentation Overview Goal
More informationSetting Specifications
536 LCGC NORTH AMERICA VOLUME 22 NUMBER 6 JUNE 2004 www.chromatographyonline.com Setting Specifications Validation Viewpoint Specifications establish the criteria to which a drug substance or product should
More informationDocumentation requirements for an initial consultation
Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,
More informationWarfarin suspension. Group B Presentation
Warfarin suspension 200mcg/ml Group B Presentation Group B - members Lene, Denmark Nihal, Turkey Jaldaz, FYROM, Mark, UK Matjaz, Slovenia Vincentas, Lithuania Juraj, Slovakia Our Business Provide service
More informationINFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES COMMISSION
EN EN EN INFORMATION FROM EUROPEAN UNION INSTITUTIONS AND BODIES COMMISSION Communication from the Commission Guideline on the details of the various categories of variations to the terms of marketing
More informationOfficial Letter from the DOH
Issued Date 2009/04/02 Issued by DOH Ref. No 0980316268 RE The DOH issued an official letter to announce the implementation of the Guideline for BA/BE Studies on April 2, 2009 (Ref. No. 0980316265). Please
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationGuide to the investigational medicinal product dossier
Guide to the investigational medicinal product dossier Item type Authors Publisher Other Irish Medicines Board (IMB) Irish Medicines Board (IMB) Downloaded 1-May-2018 07:31:12 Link to item http://hdl.handle.net/10147/96980
More informationNEWSMAGAZINE FEB 13 REGULATORY SCIENCES. AAPS ELEARNING Advanced Computer Modeling Seen as Way to Dissect Drugs Complex Effects
AAPS NEWSMAGAZINE FEB 13 REGULATORY SCIENCES AAPS ELEARNING Advanced Computer Modeling Seen as Way to Dissect Drugs Complex Effects PHARMACEUTICAL STABILITY: Doing the Right Thing versus Doing Things the
More informationAppendices! Product quality documents. Technical guidelines. (Translation from Original Chinese Version)
Appendices! (Translation from Original Chinese Version) Product quality documents Technical guidelines Appendix I General tests for various dose forms of pcms The general tests for various dose forms of
More informationConcept paper on the development of a guideline on quality and equivalence of topical products
1 2 3 4 5 6 7 8 2 December 2014 EMA/CHMP/QWP/558185/2014 Committee for Medicinal Products for Human use (CHMP) Concept paper on the development of a guideline on quality and equivalence of topical Draft
More informationASEAN GUIDELINE ON STABILITY STUDY OF DRUG PRODUCT. Version 4.0. Update revision : May Document Control
ASEAN GUIDELINE ON STABILITY STUDY OF DRUG PRODUCT Version 4.0 Update revision : May 2012 Document Control Version Date 1.0 July 2004 (8 th ACSQ PPWG Meeting; Bangkok) 2.0 February 2005 (9 th ACSQ PPWG
More informationOutline CLINICALLY RELEVANT SPECIFICATIONS. ISPE Process Validation Conference September 2017 Bethesda, MD
CLINICALLY RELEVANT SPECIFICATIONS Patrick J Marroum Ph.D. Senior Director and ACOS Senior Research Fellow Department of Clinical Pharmacology and Pharmacometrics Abbvie Pharmaceuticals Outline CMC variables
More informationQuality Assessment & GMP Similarities & Differences
Quality Assessment & GMP Similarities & Differences EMEA, Monday 26 th October 2009 Cormac Dalton Inspector Irish Medicines Board Date 12-Oct-09 Slide 1 Content Overview of commonalities & differences
More informationPublic Assessment Report. Scientific discussion. Brinzolamide Sandoz 10 mg/ml, eye drops, suspension. (brinzolamide) NL/H/2900/001/DC
Public Assessment Report Scientific discussion Brinzolamide Sandoz 10 mg/ml, eye drops, suspension (brinzolamide) NL/H/2900/001/DC Date: 18 November 2014 This module reflects the scientific discussion
More informationDEPARTMENT OF AGRICULTURE, FORESTRY & FISHERIES STABILITY
DEPARTMENT OF AGRICULTURE, FORESTRY & FISHERIES STABILITY This guideline is intended to provide recommendations to applicants wishing to submit applications for the registration of Stock Remedies. It represents
More informationSCIENTIFIC DISCUSSION
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationInstitute of Pharmaceutical Technololgy and Biopharmacy University of Pécs
Institute of Pharmaceutical Technololgy and Biopharmacy University of Pécs 1 Faculty of Pharmacy H-7624 Pécs, Rókus str.2. 2 Faculty of Pharmacy Department of Pharmacetical Biotechnology Department of
More informationPublic Assessment Report. Scientific discussion. Pantoprazol SUN Pharma 40 mg, powder for solution for injection. (pantoprazole sodium sequihydrate)
Public Assessment Report Scientific discussion Pantoprazol SUN Pharma 40 mg, powder for solution for injection (pantoprazole sodium sequihydrate) NL/H/3573/001/DC Date: 17 February 2017 This module reflects
More information(Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES EUROPEAN COMMISSION
22.1.2010 Official Journal of the European Union C 17/1 (Information) INFORMATION FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGCIES EUROPEAN COMMISSION Communication from the Commission Guideline
More informationCorso di Laurea Magistrale in Chimica e Tecnologia Farmaceutiche E25. Fabbricazione Industriale dei Medicinali 4 CFU Prof.
Sezione di Tecnologia e Legislazione Farmaceutiche Maria Edvige Sangalli Corso di Laurea Magistrale in Chimica e Tecnologia Farmaceutiche E25 Fabbricazione Industriale dei Medicinali 4 CFU Prof. Andrea
More informationMODULE 1 ADMINISTRATIVE AND PRESCRIBING INFORMATION
HEALTH CANADA USE ONLY Sponsor Attestation Checklist for Abbreviated New Drug Submissions (ANDSs) Dossier ID Control Number Date/ Time of Receipt Sponsors should address the points outlined below by answering,,
More informationTable of Contents Section 1: Section 2: Section 3: Section 4: Section 5: Section 6: Section 7:
Table of Contents Section 1: Administrative Section... 1 Section 2: Active Pharmaceutical Ingredients... 7 Section 3: Finished Pharmaceutical Product... 10 Section 4: Safety/Efficacy and/or Therapeutic
More informationUS FDAs Perspective on Product Quality and Bioequivalence
US FDAs Perspective on Product Quality and Bioequivalence Vinod P. Shah, Ph. D. Pharmaceutical Consultant (Formerly with US FDA) Scientific Principles in Dissolution Methodology and Drug Testing Society
More informationRapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products
RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products Kevin Kane, Scientific Director, BCP 7 th Annual Global Drug Delivery & Formulation Summit 28 th August
More informationWHO GENERAL GUIDANCE ON VARIATIONS TO MULTISOURCE PHARMACEUTICAL PRODUCTS. (February 2014)
February 2014 Draft for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 World Health Organization 2014 All rights reserved.
More informationPharmaceutical Regulatory Authority GUIDELINE ON APPLICATION FOR REGISTRATION OF UNREGISTERED VETERINARY MEDICINES ALREADY ON THE ZAMBIAN MARKET
GUIDELINE ON APPLICATION FOR REGISTRATION OF UNREGISTERED VETERINARY MEDICINES ALREADY ON THE ZAMBIAN MARKET ABBREVIATIONS µg Microgram API Active Pharmaceutical Ingredient ATC Anatomic Therapeutic Chemical
More informationVaccine Assessment for Prequalification and Programmatic Suitability for Prequalification
Vaccine Assessment for Prequalification and Programmatic Suitability for Prequalification Dr Drew Meek Prequalification Team/Vaccines Assessment Regulation of Medicines and other Health Technologies World
More informationNotifications process: requests to vary registered medicines where quality, safety and efficacy are not affected
Notifications process: requests to vary registered medicines where quality, safety and efficacy are not affected Version 1.0, June 2017 (pending legislative amendments) 8 June 2017 For information only.
More informationBIOPHARMACEUTICS CLASSIFICATION SYSTEM-BASED BIOWAIVERS - M9
BIOPHARMACEUTICS CLASSIFICATION - M9 Step 2 document to be released for comments Date 7 June 2018 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 Legal
More informationGuideline on the Requirements for Quality Documentation Concerning Biological Investigational Medicinal Products in Clinical Trials
1 2 3 18 February 2010 EMA/CHMP/BWP/534898/2008 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the Requirements for Quality Documentation Concerning Biological Investigational
More informationThe 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability. WHO Biowaiver Guideline in Regulatory Practice
The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability WHO Biowaiver Guideline in Regulatory Practice Dr Kamel IDDIR General Director Medicines and Pharmacy Directorate Berne
More informationEN Official Journal of the European Union. (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 1084/2003.
L 159/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 1084/2003 of 3 June 2003 concerning the examination of variations to the terms of a marketing authorisation for medicinal
More informationGood practices in quality control in pharmaceutical industry - Overview of regulatory guidelines
Review Article Good practices in quality control in pharmaceutical industry - Overview of regulatory guidelines Chagi Venkatesh*, S. B. Puranik ABSTRACT Good practices in quality control (QC) department
More informationQbD implementation in Generic Industry: Overview and Case-Study
QbD implementation in Generic Industry: Overview and Case-Study Inna Ben-Anat, QbD Strategy Leader, Teva Pharmaceuticals IFPAC JAN 2013 R&D Three Core Components of QbD and Generic Industry: How Do They
More informationConsultation response: Dissolution testing in BP finished products monographs for solid oral dosage forms
Consultation response: Dissolution testing in BP finished products monographs for solid oral dosage forms Background Oral dosage forms are the most convenient and widely used drug presentations. For solid
More informationto The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 Printed by UPPC, Entebbe, by Order of the Government No. 29.
STATUTORY INSTRUMENTS SUPPLEMENT No. 8 28th March, 2014 STATUTORY INSTRUMENTS SUPPLEMENT to The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 Printed by UPPC, Entebbe, by Order of the Government.
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationDevelopment of paediatric formulations - points to consider
Development of paediatric formulations - points to consider Workshop on Paediatric Formulations II London, 8 November 2011 Presented by: Ann Marie Kaukonen Scientific Administrator, Paediatric Medicines,
More informationQuality aspects Overview. QP declaration
Quality aspects Overview QP declaration Standards for the quality part of the dossier with focus on: - Materials from animals, nosodes - Proof of microbiological quality, pesticides, heavy metals, organic
More information